MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023


	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Balance at January 1, 2023		796,985	$	6.04		5.16
Issued		—		—
Exercised		—		—
Expired		—		—
Balance at March 31, 2023		796,985	$	6.04		4.91

Summary of Activity and Information regarding Outstanding and Exercisable Options

The following table summarizes the activity and information regarding MAIA’s outstanding and exercisable options for the three months ended March 31, 2023:


	Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Balance at January 1, 2023		6,545,628	$	2.55		7.59		—
Granted		672,287		4.08
Exercised		—		—
Cancelled/forfeited		—		—
Balance at March 31, 2023		7,217,915	$	2.69		7.82	$	8,907,071
Options exercisable at March 31, 2023		5,676,837	$	2.29		7.39	$	8,591,943

Assumptions used in Calculating Value of Options Granted

The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the three months ended March 31, 2023 and 2022:


	2023	2022
Risk-free interest rate	3.64% -4.23%		2.14	%
Expected term (in years)	5 - 6.08	5 - 6.25
Expected volatility	99.6% - 101.1%	72.0% - 74.2%
Expected dividend yield	—%	—%

Summary of Stock Based Compensation Expense

Stock based compensation related to the Company’s stock plans are as follows:



	Three Months Ended
	March 31,
	2023		2022
General and administrative	$	256,677	$	440,551
Research and development		280,845		272,779
Total stock-based compensation	$	537,522	$	713,330